Bristol Myers Squibb stock gains support from pediatric Camzyos data

Bristol Myers Squibb presented 56-week results from the Phase 3 SCOUT-HCM trial on Friday, November 6, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago. The company's investor release said the data support continued evaluation of Camzyos, or mavacamten, in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

Bristol Myers Squibb stock traded at 55.65 euros on Lang & Schwarz at 13:32 CET on Tuesday, November 10. The quote provides the current European trading indication for the shares while the latest clinical update keeps attention on the company's cardiovascular portfolio.

Trial Results Support Continued Treatment

SCOUT-HCM enrolled 44 patients aged 12 to under 18. The randomized, double-blind, placebo-controlled study began with a 28-week period, after which 43 participants entered active treatment through Week 56. Patients initially assigned to placebo switched to Camzyos, allowing the study to assess the treatment response after crossover as well as during continuous therapy.

In the group receiving mavacamten throughout the study, the mean change from baseline in the Valsalva left ventricular outflow tract gradient was -48.1 mmHg at Week 56. The placebo-to-mavacamten group achieved a similar degree of gradient reduction after switching to active treatment. Bristol Myers Squibb also reported meaningful improvements in several secondary endpoints across both groups.

The safety findings were consistent with earlier SCOUT-HCM results, according to the company. No patient experienced a left ventricular ejection fraction below 50% during the 56-week evaluation, and no new safety signals were reported. The continuous-treatment group recorded five treatment-related treatment-emergent adverse events and two serious treatment-related events over 56 weeks; the crossover group recorded one and zero, respectively, during its 28-week Camzyos exposure.

Approval Broadens Commercial Relevance

The update follows the U.S. Food and Drug Administration's September 2026 approval of Camzyos for pediatric patients weighing at least 30 kilograms with symptomatic obstructive hypertrophic cardiomyopathy. The approval was based on the earlier 28-week SCOUT-HCM results. Bristol Myers Squibb said the 56-week findings are consistent with those results and add longer-term evidence for the newly expanded indication.

For investors, the data add support to the commercial reach of a cardiovascular medicine that already serves adult patients with symptomatic obstructive hypertrophic cardiomyopathy. The trial remains an evaluation of clinical efficacy and safety rather than a financial forecast, and ongoing follow-up will be relevant as pediatric use expands.

US market context is covered in current S&P 500 market reports.

More news and analyses are available on Bristol Myers Squibb stock.